Large-scale CSF and plasma proteomics reveal immune, synaptic, and extracellular matrix disruptions across neurodegenerative diseases
Neuron, 2026
Ali M., Timsina J., Xu Y., Chen Y., Gong K., Western D., Heo G., Liu M., Budde J., Pottier C., Schindler S., Morris J., Holtzman D., Puerta R., Cano A., Boada M., Fernandez M., Ruiz A., Aguilar M., Alvarez I., Pastor P., Perlmutter J., Campbell M., Kotzbauer P., Oh H., Wilson E., Guen Y., Tarawneh R., Wyss-Coray T., Sung Y., Ibanez L., Cruchaga C.
| Disease area | Application area | Sample type | Products |
|---|---|---|---|
Neurology | Cross-platform Validation | CSF |  Olink Explore HT |
Abstract
Neurodegenerative diseases (NDs), including Alzheimer’s disease (AD), Parkinson’s disease (PD), dementia with Lewy bodies (DLB), and frontotemporal dementia (FTD), share overlapping clinical and pathological features. We analyzed cerebrospinal fluid (CSF) and plasma proteomes from 2,705 and 3,009 samples, respectively, across these NDs, identifying disease-specific and shared molecular signatures. CSF showed more disease-associated proteins than plasma, with AD and DLB exhibiting the strongest cross-tissue similarity. Pathway analyses revealed shared dysregulation of immune-related processes in CSF and plasma across the NDs, as well as disease-specific impairment of glycosylation and apoptotic pathways in AD; ATF4 and PERK signaling in PD; fibroblast growth factor receptor (FGFR) and interleukin signaling in DLB; and glycoprotein hormones disruption in FTD. We developed disease-specific predictive models showing high accuracy (area under the curve [AUC]: 0.81–0.95 in CSF and 0.80–0.89 in plasma). These findings reveal distinct and convergent mechanisms across NDs, highlighting potential biomarkers and pathways for diagnostic and therapeutic strategies in neurodegeneration.